Abstracts | 27 nicotinic and muscarinic receptors have been shown in animal models to contribute to restoring cognitive function in various rodent models of CIAS while excessive D 2 receptor blockade has a negative influence on cognition.
This presentation will focus on topics 2) and 3).
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Title: The antipsychotic drug deadlock -causes and solutions Abstract It has been a matter of debate for more than a decade whether second-generation antipsychotics (SGAs) represent an advantage over first generation compounds (FGAs). Especially the "effectiveness" studies (CATIE, CUtLASS, EUFEST) could not unequivocally confirm the superiority of SGAs over FGAs. It has been even questioned whether there was any progress in schizophrenia drug treatment since the introduction of clozapine. We have recently demonstrated in the multicentre, randomised, double-blind "Neuroleptic Strategy Study" (NeSSy; Gründer et al., 2016 ) that quality of life was statistically and clinically significantly more improved with SGAs compared to FGAs, when selection of the antipsychotic was individualised for each specific patient. SGAs might represent a significant advantage in terms of quality of life, as judged by patients. Based on ratings of psychopathology by clinicians, however, SGAs did not differ significantly from FGAs. The randomised, placebo-controlled trial in parallel groups is considered the gold standard for the evaluation of novel pharmaceuticals (Stroup et al., 2006) , although this trial design does not take into account the marked patient heterogeneity characterizing schizophrenia nor the profound disparity in the pharmacological profile of antipsychotics. We suggest that novel study-designs are needed to take into account marked patient heterogeneity and to allow for establishing individual clinical drug profiles (Schulz et al., 2016) . In addition, current clinical endpoints completely ignore the patient perspective (social function, quality of life, subjective well-being), and they are usually obtained in short-term studies, which neglect longterm outcomes. The recent discussion about the potential negative effects of long-term antipsychotic treatment on brain structure and the finding that patients with less antipsychotic exposure might have better outcomes urge for the development of new study designs with very long observation periods and new patient-oriented outcomes. These new protocols have Kobe University Graduate School of Medicine Abstract Sensitivity to addictive substance is well known to vary widely among individual subjects, which hampers effective prevention and treatment of addiction. Many genetic and environmental factors are involved in sensitivity to addictive substances including opioids, methamphetamine, alcohol, and nicotine. Interestingly, we recently found that several single nucleotide polymorphisms (SNPs) which are associated with sensitivity to an addictive substance are also associated with sensitivity to other addictive substances.
Firstly, we found that the rs2952768 SNP neighboring the CREB1gene was strongly associated with the requirements for postoperative opioid analgesics after painful cosmetic surgery in a genome wide association study (GWAS), and consistent results were obtained in patients who underwent abdominal surgery. The SNP was also associated with vulnerability to severe drug dependence in patients with methamphetamine (METH) dependence, alcohol dependence, and eating disorders and a lower "Reward Dependence" score on a personality questionnaire in healthy subjects. These results demonstrate that the SNP affects both the efficacy of opioid analgesics and liability to severe substance dependence.
Secondly, we found that the nonsynonymous rs2653349 SNP (located on the gene that encodes orexin [hypocretin] receptor 2; Val308Ile) was associated with the Fagerström Test for Nicotine Dependence (FTND) score in a GWAS. This SNP was also associated with the initiation of METH use in patients with METH dependence.
Thirdly, we found that the rs2835859 SNP (located on gene that encodes G-protein-activated inwardly rectifying potassium (GIRK) channel 2 subunit) was associated with opioid analgesic sensitivity and the result was corroborated in further confirmatory study. Moreover, this SNP was also associated with susceptibility to nicotine dependence and successful smoking cessation. The results indicate that this SNP in the GIRK2 (KCNJ6) gene could serve as a marker that predicts sensitivity to analgesic and susceptibility to nicotine dependence.
These SNPs commonly associated with sensitivity to addictive substances suggest common mechanisms among vulnerabilities to addiction due to different addictive substances. Our findings may provide valuable information for the personalized prevention and treatment of addiction.
